论文部分内容阅读
探讨MDR1、GST π、p5 3、bcl 2与上皮性卵巢癌临床病理学特性的关系。 方法 :采用免疫组化SP法检测 89例不同性质卵巢组织中MDR1、GST π、p5 3、bcl 2的表达情况。结果 :①上皮性卵巢癌 ,交界性肿瘤 ,良性上皮性肿瘤 ,正常卵巢组织中四种指标的表达情况 :MDR1依次为 2 2 / 5 2 (4 2 .3 % )、3/ 9(33 .3 % )、0 / 2 1、0 / 7,GST π依次为 43/ 5 2 (82 .7% )、5 / 9(5 5 .6 % )、1/ 2 1(4 .8% )、0 / 7,p5 3依次为 34/ 5 2 (6 5 .4% )、1/ 9(11.1% )、0 /2 1、0 / 7,bcl 2依次为 31/ 5 2 (5 9.6 % )、5 / 9(5 5 .6 % )、2 / 2 1(9.5 % )、1/ 7(14.3% )。四个指标在上皮性卵巢癌中的表达率显著增高 ;②化疗耐药与MDR1和GST π相关 ;③p5 3表达与肿瘤分期和组织分化程度相关 ;bcl 2表达与一定的组织类型相关 ;④p5 3与bcl 2 ;p5 3与MDR1;bcl 2与GST π间表达具有一定相关性。结论 :MDR1、GST π、p5 3、bcl 2的过度表达在上皮性卵巢癌中常见 ,并与一定的临床病理情况有关 ;MDR1和GST π的检测有助于临床预测化疗效果 ;凋亡调节基因与耐药相关基因的关系需进一步探讨。
To investigate the relationship between MDR1, GST π, p5 3, bcl 2 and clinicopathological features of epithelial ovarian cancer. Methods: Immunohistochemical SP method was used to detect the expression of MDR1, GST π, p5 3 and bcl 2 in 89 cases of different ovarian tissues. Results: ① The expression of four indexes in epithelial ovarian cancer, borderline tumor, benign epithelial tumor and normal ovarian tissue: MDR1 was 2 2/52 (42.3%), 3/9 (33.9%). GST π were 43/5 2 (82.7%), 5/9 (5.5%), 1/2 1 (4.8%), P 5 3 followed by 34/5 2 (6.54%), 1/9 (11.1%), 0/2 2/0/7, and bcl 2 followed by 31/5 2 (9.6%) , 5/9 (55.6%), 2/2 1 (9.5%) and 1/7 (14.3%). The expression of four markers in epithelial ovarian cancer was significantly increased; ② the chemoresistance was related to MDR1 and GST π; ③p5 3 expression was correlated with tumor stage and degree of tissue differentiation; bcl 2 expression was correlated with certain tissue types; ④p5 3 And bcl 2; p5 3 and MDR1; bcl 2 and GST π expression between a certain correlation. Conclusion: The overexpression of MDR1, GST π, p5 3 and bcl 2 is common in epithelial ovarian cancer, and is related to some clinical and pathological conditions. The detection of MDR1 and GST π is helpful to the clinical prediction of the chemotherapeutic effect. The apoptosis- The relationship with drug resistance related genes needs to be further explored.